• 130 patients implanted with DurAVR® THV since start of clinical development
• Completed preparatory work for global, pivotal PARADIGM Trial
• Appointed two new Non-Executive Directors to the Board

Anteris Technologies reported financial results for the second quarter of 2025 and provided a corporate update. Key highlights include: 130 patients successfully implanted with the DurAVR® THV since the start of clinical development, with 49 patients treated year-to-date and 21 in the second quarter. The company also achieved a world-first 'double DurAVR®' implant in a patient receiving a valve-in-valve replacement in both the mitral and aortic valve positions. Anteris made considerable progress in preparatory work for the global, pivotal PARADIGM Trial, including qualifying 79 clinical sites across the U.S., Europe, and Canada, and hosting global investigator meetings. The company also continued ongoing engagement with the FDA to progress the Investigational Device Exemption (IDE) for the PARADIGM Trial. Additionally, Anteris appointed two seasoned executives, David Roberts and Gregory Moss, to its Board of Directors. Financially, the company's net operating cash outflows for the six months ended June 30, 2025 were $41.0 million, in line with the increase in clinical, regulatory, and manufacturing requirements to support the PARADIGM Trial.